AMIX (Autonomix Medical) Short-Term Debt : $1.13 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Autonomix Medical Short-Term Debt?

Autonomix Medical's Short-Term Debt for the quarter that ended in Dec. 2024 was $1.13 Mil.

Autonomix Medical's quarterly Short-Term Debt stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($1.13 Mil).

Autonomix Medical Short-Term Debt Historical Data

The historical data trend for Autonomix Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autonomix Medical Short-Term Debt Chart

Autonomix Medical Annual Data

Trend

Mar23

Mar24

Short-Term Debt

Autonomix Medical Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial				-	-	-	-	1.13

Autonomix Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Autonomix Medical Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Autonomix Medical's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Autonomix Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Autonomix Medical Inc (NAS:AMIX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380

Website

https://www.autonomix.com

Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.